System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Johnny Mahlangu is an expert in Hematology at Johannesburg Hospital (South Africa). As of October 2026, ScienceLeadR ranks Johnny Mahlangu in the top 1% of experts worldwide for Hemophilia A. Johnny Mahlangu has authored 314 publications, the most recent in 2026, and is an investigator in 30 clinical trials, 1 of them ongoing. SLR score: 1,364 (community average: 125). How the SLR is computed.

LeadR Profile

Johnny Mahlangu Johannesburg Hospital South Africa
1 364 ScienceLeadR Reputation 1364

Unlock

Register Login
Network Map

Hematology

Subspecialties: Genetics - Public Health - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2004 - 2026
Source: PubMed

University of the Witwatersrand

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 314

Citations

Citations: 12 147 1st author: 50 Last author: 41 Unique author: 21

Main journals

Blood 67
Haemophilia 58
Res Pract Thromb Haemost 29
J Thromb Haemost 28
Hamostaseologie 11

Best Journals

N Engl J Med 10

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Future management of hemophilia A with non-biologic hemostatic agents: a call for precision coagulation.
PMID 42731015 — hemostatics, drug therapy, biomarkers, pharmacology, hemophilia a, therapeutics, biological therapy, hemostasis		Expert Opin Pharmacother20260
Recombinant activated factor VIIa for severe postpartum hemorrhage in Africa: Evidence, appropriate use, and research priorities-A narrative review.
PMID 42929449 — registries, hemorrhage, postpartum hemorrhage, factor viia, maternal mortality, research, postpartum period, hemostasis		Int J Gynaecol Obstet20260
What's New and What's Next for Emicizumab for the Treatment of Hemophilia A?
PMID 42928872 — genes, immune tolerance, safety, hemorrhage, hemophilia a, therapeutics		Biologics20260
Designing for success in early-phase hemophilia clinical trials: historical lessons and emerging principles for next-generation therapeutics.
PMID 42911026 — genes, safety, genome, hemophilia a, therapeutics		Expert Opin Investig Drugs20260
An evaluation of denecimig for bleeding prophylaxis in hemophilia A.
PMID 42762060 — safety, hemorrhage, metrorrhagia, hemophilia a, therapeutics, biological therapy		Expert Opin Biol Ther20260

Clinical Studies 30

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

Phase 3 19
Phase 2 6
N/A 2
Phase 1 1
Phase 2/Phase 3 1
Phase 4 1

By status:

Completed 27
Active not recruiting 1
Recruiting 1
Terminated 1

By type:

Interventional 28
Observational 2

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 1
multicentric5to9 1
multicentricup10 26

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study of Elritercept to Treat Anemia in Adults With Very Low Low or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
NCT06499285 — blood transfusion, myelodysplastic syndromes, safety, blood, anemia, neoplasms, therapeutics		Phase 3Recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS